The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)
Official Title: Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial.
Study ID: NCT05538689
Brief Summary: In this project, the proposition is that the use of daily dosed Myfembree ( a combination of relugolix with estradiol and norethindrone acetate), FDA-approved medication to treat heavy menses fibroid-related symptoms, has the potential to delay the recurrence of fibroid symptoms, prolong the improved quality of life and delay the need for re-intervention after uterine sparing surgery versus the routine standard of care.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: Yes
University of Chicago South Loop, Chicago, Illinois, United States
University of Chicago River East, Chicago, Illinois, United States
University of Chicago DCAM, Chicago, Illinois, United States
University of Chicago Flossmoor, Flossmoor, Illinois, United States
University of Chicago Orland Park, Orland Park, Illinois, United States
University of Chicago Schererville, Schererville, Indiana, United States
Name: Obianuju Sandra Madueke Laveaux, MD MPH
Affiliation: University of Chicago
Role: PRINCIPAL_INVESTIGATOR